Compare Abeona Therapeutics Inc (ABEO) vs ACADIA Pharmaceuticals Inc. (ACAD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs ACADIA Pharmaceuticals Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while ACADIA Pharmaceuticals Inc. trades at $29.42 (market cap $5.07B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 12× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | ACAD | |
|---|---|---|
Market Cap | $421.19M | $5.07B |
Sector | Health | Health |
52-Week High | $7.45 | $29.41 |
52-Week Low | $4.17 | $20.06 |
Enterprise Value | $276.10M | $4.19B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →
